問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of Radiation Therapy

Division of Thoracic Medicine

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-11-06

陳三奇Chen, San-Chi
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

97Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳三奇

List

125Cases

2025-09-01 - 2030-06-30

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2025-09-24 - 2028-11-30

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-10-01 - 2030-12-24

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-11-07 - 2029-09-25

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2026-02-23 - 2029-04-23

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2026-04-17 - 2028-08-02

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting4Sites

2026-07-24 - 2032-07-21

Phase II/III

Not yet recruiting
A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

  • Condition/Disease

    Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

  • Test Drug

    注射劑 注射劑 注射劑 注射劑 錠劑 注射劑 錠劑

Participate Sites
3Sites

Not yet recruiting3Sites

2017-01-17 - 2020-09-30

Phase III

Completed
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER

  • Condition/Disease

    Gastric Cancer,Gastroesophageal Junction Cancer

  • Test Drug

    Nivolumab/Ipilimumab/Oxaliplatin/Fluorouracil/Leucovorin/Capecitabine

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

洪逸平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-01-01 - 2028-12-31

Phase II

Active
A Phase II, Dose-randomization, Open-label Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy (OASES)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Para-Toluenesulfonamide (PTS)

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2025-03-01 - 2030-02-01

Phase III

Active
A multicenter, randomized, open-label, phase III trial (DESTINY-Gastric05) evaluating trastuzumab Deruxtecan (Enhertu®) with chemotherapy (with or without pembrolizumab) versus chemotherapy with or without trastuzumab as first-line treatment for patients with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

  • Condition/Disease

    HER2-positive gastric cancer or gastroesophageal junction cancer

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd)

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB